<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Document</title>
</head>
<body>
  <h1>第 5 节可吸入 VS 打三针，谁是疫苗之王？</h1>
  <p>我们比较一下康希诺和智飞生物<span class=" fw-cl "><span>，</span></span>看看谁的新冠疫苗更有优势<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>康希诺用的是<strong>腺病毒载体技术</strong><span class=" fw-cl "><span>，</span></span>也就是用腺病毒把 S 蛋白的 mRNA 送到人体细胞内<span class=" fw-cl "><span>，</span></span>然后让人体细胞生产抗原 S 蛋白<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>目前有四种已经上市的疫苗采用了腺病毒载体这一技术路径<span class=" fw-cl "><span>，</span></span>分别是阿斯利康和牛津大学合作的 AZD1222<span class=" fw-cl "><span>，</span></span>强生疫苗<span class=" fw-cl "><span>，</span></span>俄罗斯 Gamaleya 研究所的卫星 5 号<span class=" fw-cl "><span>，</span></span>还有我国康希诺生物和陈薇院士合作的克威莎<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>而所有使用腺病毒载体的疫苗都会遇到同一个难题<span class=" fw-cl "><span>，</span></span>也就是所谓的<span class="fw-op  "><span>「</span></span>预存免疫<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>什么是<strong>预存免疫</strong>呢<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>腺病毒是一种人源病毒<span class=" fw-cl "><span>，</span></span>很有可能接种疫苗的人曾经感染过腺病毒<span class=" fw-cl "><span>。</span></span></p>
<p>这样的话<span class=" fw-cl "><span>，</span></span>当腺病毒载体带着重要<span class="fw-op  "><span>「</span></span>信息<span class=" fw-cl "><span>」</span></span>——S 蛋白的 mRNA 进入人体时<span class=" fw-cl "><span>，</span></span>人体的免疫系统会问一个<span class="fw-op  "><span>「</span></span>尖锐<span class=" fw-cl "><span>」</span></span>的问题<span class=" fw-cl "><span>：</span></span><span class="fw-op  fw--collapsed"><span>「</span></span>你还记得大明湖的夏雨荷吗<span class=" fw-cl fw--collapsed"><span>？</span></span><span class=" fw-cl "><span>」</span></span></p>
<p>然后免疫系统就会把腺病毒就地正法<span class=" fw-cl "><span>，</span></span>却忘了查看腺病毒带来的信息<span class=" fw-cl "><span>。</span></span>这样疫苗的效果就会大打折扣<span class=" fw-cl "><span>。</span></span>这就是<span class="fw-op  "><span>「</span></span>预存免疫<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>为了解决这个问题<span class=" fw-cl "><span>，</span></span>阿斯利康用来自黑猩猩的腺病毒做载体<span class=" fw-cl "><span>，</span></span>强生用了相对少见的 Ad26<span class=" fw-cl "><span>，</span></span>卫星 5 号则用了 Ad26 和 Ad5 各打一针<span class=" fw-cl "><span>，</span></span>东边不亮西边亮<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>而正因为应用了比较新的腺病毒载体<span class=" fw-cl "><span>，</span></span>阿斯利康和强生疫苗出现了极小比例的严重不良反应<span class=" fw-cl "><span>，</span></span>可能会引发血栓<span class=" fw-cl "><span>。</span></span>为此这两家疫苗也一度被欧美暂停使用<span class=" fw-cl "><span>。</span></span>不过在统计了血栓发生的比例后<span class=" fw-cl "><span>，</span></span>监管机构表示疫苗的<span class="fw-op  "><span>「</span></span>益处大于风险<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>。</span></span></p>
<p>目前<span class=" fw-cl "><span>，</span></span>这两种疫苗仍在世界范围内广泛使用<span class=" fw-cl "><span>。</span></span>只有丹麦<span class=" fw-cl "><span>、</span></span>挪威奥地利三国停用了阿斯利康疫苗<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>而康希诺采用的是比较成熟的 <strong>Ad5 腺病毒载体</strong><span class=" fw-cl "><span>，</span></span>目前在国内接种已经超过 2000 万剂<span class=" fw-cl "><span>，</span></span>没有发现血栓问题<span class=" fw-cl "><span>，</span></span>主要的不良反应是发热<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>那康希诺是怎么解决预存免疫问题的呢<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>原来我国科研人员在研发埃博拉疫苗时发现<span class=" fw-cl "><span>，</span></span>随着抗原剂量的提升<span class=" fw-cl "><span>，</span></span>预存免疫影响越来越小<span class=" fw-cl "><span>。</span></span>而在新冠疫苗临床试验中<span class=" fw-cl "><span>，</span></span>也证明了即使感染过腺病毒的人也能激发足够的免疫反应<span class=" fw-cl "><span>。</span></span></p>
<p>而且在第一针后 6 个月接种加强针后<span class=" fw-cl "><span>，</span></span>中和抗体水平能够提升 7-10 倍<span class=" fw-cl "><span>，</span></span>这充分说明了康希诺已经解决了预存免疫的问题<span class=" fw-cl "><span>。</span></span>因为如果有<span class="fw-op  "><span>「</span></span>预存免疫<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>，</span></span>第二针理论上应该是无效的<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>康希诺疫苗在全球的三期临床试验数据显示<span class=" fw-cl "><span>，</span></span>在单针接种疫苗 28 天后<span class=" fw-cl "><span>，</span></span>对重症新冠肺炎的保护效力为 90.98%<span class=" fw-cl "><span>，</span></span>总体保护效力为 65.7%<span class=" fw-cl "><span>，</span></span>算得上<span class="fw-op  "><span>「</span></span>老军医一针见效了<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<figure class="central"><img data-src="https://pic2.zhimg.com/v2-d841bc86e75414af5d591224e12653da.png?source=6a64a727" alt="" class="richText-img-source"><span class="processImgLazyload-placeholder-e5egJ richText-img-placeholder" style="padding:27.437499999999996% 0" data-src="https://pic2.zhimg.com/v2-d841bc86e75414af5d591224e12653da.png?source=6a64a727">加载中...</span></figure>
<p>不过康希诺还有更让人期待的在研品种<span class=" fw-cl "><span>，</span></span>那就是<span class="fw-op  "><span>「</span></span>吸入式新冠疫苗<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>这是一种<span class="fw-op  "><span>「</span></span>双非<span class=" fw-cl "><span>」</span></span>疫苗<span class=" fw-cl "><span>，</span></span>非冷链<span class=" fw-cl "><span>，</span></span>非注射<span class=" fw-cl "><span>，</span></span>而且还有三重免疫<span class=" fw-cl "><span>，</span></span>不仅可以激活体液免疫<span class=" fw-cl "><span>、</span></span>细胞免疫<span class=" fw-cl "><span>，</span></span>还能激活黏膜免疫<span class=" fw-cl "><span>，</span></span>在第一道关卡就能把新冠病毒挡住<span class=" fw-cl "><span>。</span></span></p>
<p>最关键的是<span class=" fw-cl "><span>，</span></span><span class="fw-op  fw--collapsed"><span>「</span></span>吸入式新冠疫苗<span class=" fw-cl "><span>」</span></span>的用量是注射式的五分之一<span class=" fw-cl "><span>，</span></span>也就是说康希诺的产能一下子就从 5 亿剂扩充到 25 亿剂<span class=" fw-cl "><span>，</span></span>同时还突破了疫苗瓶子的<span class="fw-op  "><span>「</span></span>瓶颈<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>。</span></span></p>
<p>2021 年 6 月 3 号<span class=" fw-cl "><span>，</span></span>陈薇院士在浦江创新论坛上宣布这种疫苗正在申请紧急使用<span class=" fw-cl "><span>。</span></span></p>
<p>想象一下<span class=" fw-cl "><span>，</span></span>现在接种一针康希诺疫苗<span class=" fw-cl "><span>，</span></span>6 个月后选择可吸入疫苗当作加强<span class=" fw-cl "><span>，</span></span>这对于我这种<span class="fw-op  "><span>「</span></span>恐针<span class=" fw-cl "><span>」</span></span>人群还真的是非常有诱惑力<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>和只要打一针的康希诺不同<span class=" fw-cl "><span>，</span></span>智飞龙科马和中科院合作的重组蛋白亚单位疫苗就有点不招人喜欢了<span class=" fw-cl "><span>，</span></span>居然要打三针<span class=" fw-cl "><span>。</span></span></p>
<p>这是为什么呢<span class=" fw-cl "><span>？</span></span></p>
<p>主要是因为临床试验显示<span class=" fw-cl "><span>，</span></span>接种两针后<span class=" fw-cl "><span>，</span></span>76% 的人产生了中和抗体<span class=" fw-cl "><span>，</span></span>而接种三针后<span class=" fw-cl "><span>，</span></span>97% 的人产生了中和抗体<span class=" fw-cl "><span>，</span></span>而且抗体浓度达到了新冠康复者的 2 倍<span class=" fw-cl "><span>。</span></span></p>
<p>也就是说需要接种三针才能达到最理想的免疫效果<span class=" fw-cl "><span>，</span></span>同种技术路线的乙肝疫苗和 HPV 疫苗也都是三针剂型<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>我们在前面讲过这种疫苗的原理<span class=" fw-cl "><span>。</span></span>智飞选择了 S 蛋白上最为关键的 RBD 结构域<span class=" fw-cl "><span>，</span></span>也就是新冠病毒用来开指纹锁的那根手指<span class=" fw-cl "><span>。</span></span>在体外大量生产 RBD 蛋白<span class=" fw-cl "><span>，</span></span>然后注射到体内作为抗原<span class=" fw-cl "><span>，</span></span>激活针对 RBD 结构的抗体<span class=" fw-cl "><span>。</span></span></p>
<p>但和完整的新冠病毒相比<span class=" fw-cl "><span>，</span></span>RBD 蛋白还是太弱小了<span class=" fw-cl "><span>，</span></span>即使加了佐剂<span class=" fw-cl "><span>，</span></span>还是需要三次才能让免疫系统彻底记住<span class=" fw-cl "><span>。</span></span></p>
<p>这类疫苗最大的优点就是安全<span class=" fw-cl "><span>，</span></span>无论是生产还是使用<span class=" fw-cl "><span>，</span></span>都是最安全的水平<span class=" fw-cl "><span>。</span></span>而且体外重组蛋白的工艺非常成熟<span class=" fw-cl "><span>，</span></span>产能扩张非常方便<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>不过三针剂型的确是不太友好<span class=" fw-cl "><span>，</span></span>尤其是智飞生物当前的年产能只有 3 亿剂<span class=" fw-cl "><span>，</span></span>很多地方出现了断货的情况<span class=" fw-cl "><span>。</span></span>不过智飞生物的产能瓶颈主要是卡在了灌装上<span class=" fw-cl "><span>，</span></span>后续的提升速度会比较快<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>智飞生物是现在市值最高的中国疫苗企业<span class=" fw-cl "><span>，</span></span>康希诺生物则是新冠疫情以来涨幅最大的中国疫苗企业<span class=" fw-cl "><span>。</span></span>它们两家也不负众望<span class=" fw-cl "><span>，</span></span>都成功研发出了合格的新冠疫苗<span class=" fw-cl "><span>。</span></span></p>
<p>那么谁的新冠疫苗更有优势呢<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>我们认为<span class=" fw-cl "><span>，</span></span>现阶段是国内接种人数上升的加速期<span class=" fw-cl "><span>，</span></span>充分体现了有什么打什么的原则<span class=" fw-cl "><span>。</span></span> 这时候<span class=" fw-cl "><span>，</span></span>只需要打一针的康希诺无疑更受欢迎<span class=" fw-cl "><span>，</span></span>毕竟是<span class="fw-op  "><span>「</span></span>一针起效<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>。</span></span></p>
<p>而且现阶段<span class=" fw-cl "><span>，</span></span>康希诺的年产能是 5 亿剂<span class=" fw-cl "><span>，</span></span>智飞生物是 3 亿剂<span class=" fw-cl "><span>，</span></span>也就是康希诺能覆盖 5 亿人<span class=" fw-cl "><span>，</span></span>智飞只能覆盖 1 亿人<span class=" fw-cl "><span>。</span></span>在 6 月 10 号到 30 号<span class=" fw-cl "><span>，</span></span>停止接种第一针的期间<span class=" fw-cl "><span>，</span></span>康希诺是完全不受影响的<span class=" fw-cl "><span>。</span></span></p>
<p>虽然江苏现在正在试点先打一针康希诺<span class=" fw-cl "><span>，</span></span>后面再补一针智飞<span class=" fw-cl "><span>。</span></span>但后续的加强针大概率还是使用同厂家或者同类型的疫苗<span class=" fw-cl "><span>。</span></span>应该说在新冠疫苗这个点上<span class=" fw-cl "><span>，</span></span>康希诺跑在了前面<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p><strong>但智飞生物成为<span class="fw-op  "><span>「</span></span>疫苗茅<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>，</span></span>它的核心竞争力从来都不是研发能力<span class=" fw-cl "><span>，</span></span>而是销售能力<span class=" fw-cl "><span>。</span></span></strong></p>
<p>智飞有 1800 多人的销售团队<span class=" fw-cl "><span>，</span></span>比 A 股其他疫苗企业加起来还要多<span class=" fw-cl "><span>。</span></span>这就是为什么默沙东会选择智飞作为自己的合作伙伴<span class=" fw-cl "><span>，</span></span>把自己家下金蛋的鸡养在智飞家里<span class=" fw-cl "><span>。</span></span></p>
<p>而康希诺则却是以研发驱动的公司<span class=" fw-cl "><span>，</span></span>研发人员占比超过 30%<span class=" fw-cl "><span>，</span></span>研发管线也堪称豪华<span class=" fw-cl "><span>。</span></span>新冠疫苗的营收<span class=" fw-cl "><span>，</span></span>更是让公司拥有了充沛的现金流<span class=" fw-cl "><span>，</span></span>发展速度惊人<span class=" fw-cl "><span>。</span></span></p>
<p>以国内市场来看<span class=" fw-cl "><span>，</span></span>新冠疫情让所有的疫苗生产企业都获得了加速的机会<span class=" fw-cl "><span>，</span></span>智飞生物的领跑优势相对被削弱了<span class=" fw-cl "><span>。</span></span></p>
<p>但新冠疫苗并不能决定谁是真正的疫苗之王<span class=" fw-cl "><span>，</span></span>它只是通向王座的工具<span class=" fw-cl "><span>。</span></span>真正决定王座归属的<span class=" fw-cl "><span>，</span></span>是这些疫苗企业的研发管线<span class=" fw-cl "><span>，</span></span>尤其是对于 mRNA 技术的布局和研究<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>不过国内的疫苗之王并不是这些企业的终点<span class=" fw-cl "><span>，</span></span>走出国门<span class=" fw-cl "><span>，</span></span>放眼世界<span class=" fw-cl "><span>，</span></span>才是时代赋予它们的机会<span class=" fw-cl "><span>。</span></span></p>
<div class="customizeRender" data-tag="video" data-resource-id="1479494970600435713" data-is-green="false" data-add-head-tail="true" data-cover-url=""></div>
<p><br></p><p><span style="display:block;font-size: 13px;opacity:0.5;transform:translateY(-20px);">备案号:YXX11Zej0ntkjx0PzibJlp</span></p>
</body>
</html>